Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tivicay was produced by AbbVie and Eisai.

GSK to sell off part of its HIV venture ViiV Healthcare

GSK to sell off part of its HIV venture ViiV Healthcare ViiV, set up in 2009 as a partnership between GSK and Pfizer, has been growing strongly, buoyed by sales of integrase inhibitor Tivicay (dolutegravir) and the fixed dose combination Epzicom ... GSK's CEO Andrew Witty said ViiV had made “very

ViiV bags US approval for HIV blockbuster-in-waiting

ViiV bags US approval for HIV blockbuster-in-waiting Drug combines antiretrovirals with Tivicay. HIV specialist ViiV Healthcare looks set to roll out a second potential blockbuster in 12 months after getting approval in the US for new triple combination ... Triumeq combines ViiV's antiretroviral stalwarts

Biosimilar Lantus leads CHMP opinions

Biosimilar Lantus leads CHMP opinions Triumeq – a combination of already-approved treatments Tivicay (dolutegravir) and Kivexa (abacavir/lamivudine) – was recommended to treat HIV infection in adults and adolescents aged 12 years and older.

Second darapladib failure disappoints GSK

Second darapladib failure disappoints GSK There have been recent approvals for respiratory drugs Breo (fluticasone/vilanterol) and Anoro (umeclidinium/vilanterol), HIV therapy Tivicay (dolutegravir; sold by joint venture ViiV) and Tanzeum (albiglutide) for diabetes, as well

Developing your patient-centric strategy

Developing your patient-centric strategy The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company's HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

[ Previous 5 results ] 3 4 5 6 7 8 9 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...